Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,901–3,000 of 3,704
Annesi, J. J., & Machek, S. B. (2025) · Obesities · doi:10.3390/obesities5040083
EndoCompass Project: Research Roadmap for Diabetes, Obesity, and Metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000549194 · Cited by 1
Continuity of care in obesity clinical care
Lesmes, I. B., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2025.501658 · Cited by 1
Powell, D. R., Sligtenhorst, I. V., Main, A. J., Jin, H., Carson, K. G., Shi, Z.-C., Swaffield, J. C., Smith, M. G., Harris, A. L., Gopinathan, S., et al. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf196
The Thyroid Twist: How GLP-1 Agonists Are Influencing Autoimmune Thyroid Care
Mazza, A. D. (2025) · Cureus · doi:10.7759/cureus.98153 · Cited by 4
Zhang, J., Wang, T., Qu, Y., Yan, F., Liu, S., & Lin, R. (2025) · Statistics in Medicine · doi:10.1002/sim.70338
Quinaglia, T., Silva, G., Matos‐Souza, J. R., Coelho‐Filho, O. R., Nadruz, W., & Sposito, A. C. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01368-x
Peptide drugs for obesity and type 2 diabetes mellitus: an overview of clinical trials
Barzgar, H., Darmadi, D., Nafisa, J., Narkulov, S., & Sviridova, M. B. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120772 · Cited by 2
Palmer, R. C., Telang, S. S., Kistler, N. M., Mayfield, C. K., Hong, K. M., Gucev, G., Lieberman, J. R., & Heckmann, N. D. (2025) · European Journal of Orthopaedic Surgery & Traumatology · doi:10.1007/s00590-025-04604-x · Cited by 2
Metabolic and Bariatric Surgery in Algeria: Current Challenges and Future Directions
Mebarek, H., & Toumi, H. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-02164-z
Alvarez, G., Veliz, L., Michaels, S., Pino, D., & Wu, J. (2025) · Obesities · doi:10.3390/obesities5040090 · Cited by 1
Vutiglabridin overcomes the GLP-1 RA-associated weight-loss plateau to achieve normal body weight
Lee, H. M., Marakkalage, K. G., Kim, S. H., Lee, S., Lee, J. H., Park, H. S., & Yoo, S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02161-9
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Grycan, M., Grycan, G., & Pstrągowski, M. (2025) · Biuletyn Głównej Biblioteki Lekarskiej · doi:10.2478/bgbl-2025-0015
Weight Management Through a Woman’s Life Stages: A Practical Evidence-Based Guide
Scholcoff, C., Yecies, E. B., Worthington, R. O., & Farkas, A. H. (2025) · Journal of Women s Health · doi:10.1177/15409996251405062
Gunasekaran, V., Kapoor, V., & Chamarthi, V. S. (2025) · European Journal of Medical and Health Sciences · doi:10.24018/ejmed.2025.7.6.2453 · Cited by 1
Obesity Pharmacotherapy: A Practical Approach to Patient-Centered Medication Selection
Park, J. (2025) · Korean Journal of Family Practice · doi:10.21215/kjfp.2025.15.4.194 · Cited by 1
Lin, D., Xiao, H., Yang, K., Li, J., Ye, S., Liu, Y., Jing, S., Lin, Y., Yang, Y., Huang, L., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25918869
Chronische Niereninsuffizienz bei Typ-2-Diabetes – die stille Bedrohung einer Multisystemerkrankung
Günes-Altan, M., & Schmieder, R. (2025) · Diabetes aktuell · doi:10.1055/a-2624-4700
López, G. P. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.107122 · Cited by 2
Lerner, J. J., Schmid, L., Zorn, S., von Schnurbein, J., Siebert, R., & Wabitsch, M. (2025) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2606-2353
Bruner, W. S., Grant, S. F., & McCormack, S. E. (2024) · Wiley eBooks · doi:10.1002/9780470015902.a0029841
Continuidad asistencial en la atención clínica de la obesidad
Bretón, I., García, J. M. F., Vilarrasa, N., Arroyo, V. R., de Hollanda, A., Cortés, G. B., & Ballesteros-Pomar, M. D. (2025) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2025.501658 · Cited by 2
Current Research Status of Pharmacotherapy for Non-Alcoholic Fatty Liver Disease (NAFLD)
田, 一. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1592652
Srivastava, G., Madhar, A., & Chen, Y. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1177/29986702251380864
Modern approaches to obesity management: Is dietary intervention sufficient?
Gligorijević, J., Stevanović, S., Stanković, V. V., Zuber, A., & Avramović, D. (2025) · PONS - medicinski casopis · doi:10.5937/pomc22-53816 · Cited by 1
A consensus statement from the European Society for Clinical Investigation
Carbone, F., Després, J., Ioannidis, J. P. A., Neeland, I. J., Garruti, G., Busetto, L., Liberale, L., Ministrini, S., Vilahur, G., Schindler, T. H., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Don't Throw Willpower out the Window
Hallinan, K. (2025) · The Guthrie Clinic Journal of Medicine · doi:10.3138/guthrie-2025-0017
a systematic analysis for the Global Burden of Disease Study 2023
Hay, S. I., Ong, K. L., Santomauro, D. F., Bhoomadevi, A., Aalipour, M. A., Aalruz, H., Ababneh, H. S., Abaraogu, U. O., Abate, B. B., Abbafati, C., et al. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Micco, P. D., & Siniscalchi, C. (2025) · Italian Journal of Medicine · doi:10.4081/itjm.2025.2371
Fernandes, A., MacAulay, C., Khater, A. R., Matthews, H., Mohrir, G. S., & Lodge, C. (2025) · Cureus · doi:10.7759/cureus.99805
Chae, K., Leng, X., Neiberg, R. H., Bray, G. A., Johnson, K., Hill, J. O., Jakicic, J. M., Chao, A. M., Beavers, K. M., Pownall, H. J., et al. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01997-x · Cited by 1
Aloufi, L. K., Almaysari, R. K., Aljehani, A. T., Almalki Dhaifallah Mohammed, D., & Alnefaie, Z. M. (2025) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20254166
Li, J., Chandrashekar, A., Ravikumar, R., et al. (2025) · Pancreatology · doi:10.1016/j.pan.2025.12.021
USO DE ANÁLOGOS DE GLP-1 NO TRATAMENTO DA OBESIDADE: EVIDÊNCIAS CLÍNICAS E IMPLICAÇÕES NUTRICIONAIS
Martins, V. A., de Godoy, J. S. G. E., Macêna, M. D. L., et al. (2025) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/dgpn4685
Anti-obesity Pharmacotherapy for Patients with Genetic Obesity Disorders
Welling, M. S., van Rossum, E. F. C., & van den Akker, E. (2025) · Springer eBooks · doi:10.1007/978-3-032-04095-4_15
Comprehensive Management Strategies for Cardiovascular–Kidney–Metabolic Syndrome
Ouatu, A., & Buliga-Finiș, O. N. (2025) · Springer eBooks · doi:10.1007/978-3-032-11445-7_18
Steven, C., Skylynn, T., Bardya, H., Megha, B., Helen, V., Lee, D., Entabi, F., & Pemminati, S. (2026) · Cureus · doi:10.7759/cureus.100704 · Cited by 2
TIRZEPATIDE - A NEW ERA IN OBESITY TREATMENT? A REVIEW OF THE CURRENT STATE OF KNOWLEDGE
Solarz, A., Kryślak, J., Szabelski, S., Graczyk, E., Sokołowski, M., & Oskroba, K. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4143
Treatment Modalities for Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Review Article
Damle, V. A., Sharma, A., Srivastava, B. K., Raveendran, A. V., Seshadri, K. G., & Mohan, V. (2026) · Journal of Diabetology · doi:10.4103/jod.jod_85_25
Long-term management of body weight and physiological mechanisms of weight regain
Hu, T., & Bao, Y. (2026) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjaf062 · Cited by 1
Obesity medications and acquired hypothalamic obesity in adults: A two-case experience
Lang, H., Dorand, M. F., Hassan, M., & Richards, J. R. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100246
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Review of Medicine Surgery and Dentistry · doi:10.64907/xkmf.v5.i1.rmsd.1
Senatorska, N., Kleszczewska, K., Pruska, A., Rarok, J., Godlewska, D., Pietruszewska, H., Banaszek, M., Panfil, A., Błocka, J., & Lurka, A. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4225
Robinson, K. M., Rodriguez, S. A., Pedagarla, C., Eyck, P. T., Correia, M. L., & Dokun, A. O. (2026) · Obesity Science & Practice · doi:10.1002/osp4.70114 · Cited by 1
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Public Healthcare and Ancient Science · doi:10.64907/xkmf.v6.i1.phas.1
New and Interesting Benefits with New Molecules in Obesity and Type 2 Diabetes
Páez, F. G., Barrios, S. Z., Bautista, L. E. C., Chong, L. D. P., & Velazquez, X. G. R. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1009256
ONE DRUG TO FIX IT ALL? THE ROLE OF TIRZEPATIDE IN TREATING COMPONENTS OF METABOLIC SYNDROME
Tomasiczek, S., Tomasiczek, W., Kondyjowska, D., Sawiec, Z., Bukała, N., Komuńska, D. M., Antonowicz, E., & Rogozińska, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4180
Sraboni, A., Farhana, K. M., & Abdul, M. K. (2026) · Journal of Biotechnology and Food Engineering · doi:10.64907/xkmf.v4.i1.jbfe.1
Postmenopause und Gewicht: Wechselseitige Einflüsse und die Rolle der Hormonersatztherapie
Bachmann, A. (2026) · Die Gynäkologie · doi:10.1007/s00129-025-05459-3
Fu, L., Fan, J., Yue, X., Yang, S., Xie, X., & Zhong, J. (2026) · Medical Research Frontiers · doi:10.57237/j.mrf.2025.04.001
Jannot-Lamotte, M.-F. (2025) · Les Dossiers de l obstétrique · doi:10.54695/dosf.547.0028
Campbell, L., Fuest, S., & Jackson, C. D. (2026) · Journal of General Internal Medicine · doi:10.1007/s11606-025-10123-6
Szelka, H., Czyżykowski, K., Gęsińska, A. M., Golis, B., Edyko, P., Babula, A., Golus, W., Andrzejewska, K., Przybyła, Z., & Woźniak, H. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4323
Einfluss von Appetitzüglern auf die TCM-Akzeptanz bei (Prä‑)Adipösen
Happe, A. K., Rothe, S., Vlasak, T., et al. (2026) · Deutsche Zeitschrift für Akupunktur · doi:10.1007/s42212-025-00800-2
De Novo and Recurrent Metabolic Dysfunction Associated Steatotic Liver Disease
Parsa, L., & Satapathy, S. K. (2026) · Springer eBooks · doi:10.1007/978-981-95-2624-6_37
Sayed, A., Peterson, E., & Navar, A. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101400 · Cited by 1
Ponziani, M. C., & Chianelli, M. (2026) · Obesity and Endocrinology · doi:10.1093/obendo/wjag002
Management of metabolic dysfunction and cardiovascular risk in patients with MASLD
Danpanichkul, P., Blaney, H. L., Perelli, J., Huerta, P., Idalsoaga, F. J., Arrese, M. A., Arab, J. P., Loomba, R. S., & Díaz, L. A. (2026) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.32 · Cited by 3
Ali, D., Kudaya, D. Q., Ngige, A. A., & Chao, A. M. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0026 · Cited by 1
The Benefits and Costs of Treating Obesity Among Adults in the Medicaid Program
Livingston, T., Dall, T. M., Chen, F., Moody, A., Ferguson, C. C., Sapra, T., ElSayed, N. A., Hafida, S., & Bannuru, R. R. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci25-0005 · Cited by 1
Panhofer, P., Krzyzanowska-Mittermayer, K., & Rothe, S. (2026) · Deutsche Zeitschrift für Akupunktur · doi:10.1007/s42212-025-00797-8
Kim, S. H., Heo, J. H., Cunanan, K. M., & Gardner, C. D. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag015
Recombinant live biotherapeutics against chronic metabolic diseases: Challenges and opportunities
Swamy, P., Singh, L., Sehrawat, P., & Mahajan, D. (2026) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2026.01.008
OBE ‐ DB : A Computational Tool and Web Server for the Prediction of Obesity Drugs
García, E. M., Martínez-Cortés, C., Banegas‐Luna, A. J., Morante, J. J. H., & Pérez-Sánchez, H. (2026) · Obesity · doi:10.1002/oby.70117
Anti-obesity Pharmacotherapy for Transplant Recipients
Haugen, C. E., & Orandi, B. J. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01388-1 · Cited by 1
Tonnesen, P. T., Olesen, K. K. W., Gyldenkerne, C., Hansen, M. K., Stødkilde-Jørgensen, N., Thrane, P. G., Andersen, M. H., Poulsen, P. L., Thomsen, R. W., Sattar, N. A., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03085-4 · Cited by 1
Malmborg, M. W., El-Chouli, M. H., Andersen, C. F., Elmegaard, M., Garred, C. H., Zahir, D., Butt, J. H., Christensen, D. M., Nouhravesh, N., Fosbøl, E. L., et al. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03062-3
Beyond Diabetes: A Review of Emerging Indications for Glucagon-Like Peptide-1 Receptor Agonists
West, L. M., Patolia, H. H., Chapman, B., Laffin, L. J., Vest, A. R., Sauer, A. J., & Martyn, T. (2026) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm44528 · Cited by 1
Real-world insights into antiobesity medications in an online patient community: a feasibility studyPreprint
Kalich, B. A., Cruz, M., Shaw, S. Y., Cordova, J. M., Ke, H., Mina, M. J., Chen, B., & Burton, P. (2026) · medRxiv · doi:10.64898/2026.01.26.26344623
A potent novel small molecule GLP-1R agonist identified by rational design and CADD
Chen, J., Yao, Y., & Li, H. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118578 · Cited by 1
Serretti, A. (2026) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000614
Popescu, S., & Ionescu, A. (2023) · Annals of Pharmacy Education Safety and Public Health Advocacy · doi:10.51847/kbbmhebthm
Sikorska, L. M., Liu, V. N., Johnson, H., Chaudry, E., Reisel, D., Clift, A. K., & Huang, D. R. (2026) · Cureus · doi:10.7759/cureus.102817 · Cited by 1
Bednarczyk, R., Bednarczyk, N., Binkowski, R. K., Kurek, A., Krajewska, N., Lejman, A., Mazurkiewicz, A., Sidor, H., Wołosik, M., & Zysiak, S. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.1(49).2026.4671
Jain, V., McMullen, C. A., Kimbrough, J., Rockich, A. K., Davenport, D. L., Hawk, G. S., Nikolajczyk, B. S., Kern, P. A., Fisher, S. J., Steiner, J. P., et al. (2026) · Journal of Surgical Research · doi:10.1016/j.jss.2026.01.004
Ofili, S. C., & Chen, H. (2026) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2026.32.2.166 · Cited by 3
Ponce, J., Lutfi, R. E., Buchwald, J. N., & Peterson, R. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08503-w
Sustained clinical and economic impact of sleeve gastrectomy: Beyond weight loss
Ateca, I. V., Grijalba, O. G., Ustarroz-Aguirre, I., Acaiturri-Ayesta, T., Bilbao, A. A., Olartekoetxea, G. E., & Lasarte, A. S. (2026) · Cirugía Española (English Edition) · doi:10.1016/j.cireng.2026.800287
Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity
Newman, C. B., Saunders, K. H., Schmitz, S. H., & Subramanian, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26712-3.00020-3
Take a personalised approach to weight management for older adults with obesity
Brown, M. B. (2026) · Drugs & Therapy Perspectives · doi:10.1007/s40267-025-01213-w
Managing Obesity in Heart Failure Patients: Current Evidence and Strategies
Sharma, S., Giri, G. K., Desai, A., Ruiz, J., Gomez, V., & GOSWAMI, R. M. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.016
Jia, W., & WANG, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70556
Daggolu, J., Okonkwo, M., & Chen, H. (2026) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000002145
Lal, P. (2025) · Journal of Bariatric Surgery · doi:10.4103/jbs.jbs_1_26
Oliveira-Gomes, D. D., de Majo, A. M., Ardila-Delgado, A. D., Inglis, S. S., Mandras, S. A., Loro-Ferrer, J. F., & daSilva‐deAbreu, A. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01395-2
Jeyaretnam, J. J. (2026) · Global Journal of Obesity Diabetes and Metabolic Syndrome · doi:10.17352/gjodms.000069
Siddiqui, S. I., Tabatabaie, V., & Aleksić, S. (2026) · The Journals of Gerontology Series A · doi:10.1093/gerona/glag010
Challenges in the management of obesity
Smith, B. L., May, A., Lalani, F., Hasham, S., & Presnell, A. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.09.023 · Cited by 4
Beratung zur Adipositas – Herausforderung in der Hausarztpraxis
Uebel, T. (2026) · Allgemeinmedizin up2date · doi:10.1055/a-2080-9559
El‐Amawy, H. S. (2026) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2026.501255 · Cited by 1
Obesity in Living Kidney Donors from Risk to Ethics: Bridging Gaps in Evaluation and Management
Budhiraja, P., Bzoma, B., Đenić, A., Issa, N. S., McKee, K., Schinstock, C., Taler, S. J., Chakkera, H. A., Heimbach, J. K., Jadlowiec, C. C., et al. (2026) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000001030 · Cited by 2
Tirzepatide improves pancreatic β-cell function in mice and patients with type 2 diabetesPreprint
Li, Z., Guo, J., Cheng, Y., Zhang, T., Luo, X., Zhang, S., Ren, Q., Wu, Z., Chen, N., & Li, M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.13.704343
Self-citationLange, M. G., Vickers, A., Hill, L. J., Mollan, S. P., Mitchell, J., Sinclair, A. J., & Lee, A. G. (2026) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000002431
Prioritising nutrition alongside paediatric obesity management medications
Ruggiero, C. F., Spreckley, M., Davis, N. L., & Brown, A. C. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00008-2
Are obesity drugs causing a severe complication? What the science says
Lenharo, M. (2026) · Nature · doi:10.1038/d41586-026-00552-6
Treatment of obesity: New drugs
Berti, S., Garelli, S., & Pagotto, U. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00330-7
Lipedema: aspectos fisiopatológicos e estratégias terapêuticas – Atualização para dermatologistas
Dini, T. D., Birck, M. S., Saalfeld, R. M., Macedo, C. L. D., & Bagatin, E. (2026) · Anais Brasileiros de Dermatologia (Versão em Português) · doi:10.1016/j.abdp.2026.501270 · Cited by 1
Impacto clínico y económico sostenido de la gastrectomía vertical. Más allá de la pérdida de peso
Ateca, I. V., Grijalba, O. G., Ustarroz-Aguirre, I., Acaiturri-Ayesta, T., Bilbao, A. A., Olartekoetxea, G. E., & Lasarte, A. S. (2026) · Cirugía Española · doi:10.1016/j.ciresp.2026.800287
The role of CXCL10 in high‐fat diet–induced skeletal muscle inflammation and atrophy
Liyuan, A., Hirata, Y., Inoue, T., Sugawara, K., & Ogawa, W. (2026) · Journal of Diabetes Investigation · doi:10.1111/jdi.70270 · Cited by 1
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.